Siena Biotech is a drug discovery and development company with a consolidated portfolio of disease modifying small molecule therapeutics for oncology and neurodegenerative diseases aiming to prolong and improve the quality of patients' lives

Siena Biotech has secured top level management executives leading an established team of talented international scientists. Combining our drug discovery and development expertise with an integrated platform of cutting edge technologies housed in a purpose-built research centre, we have developed a diversified pipeline of partnered, in licensed and proprietary products for oncology and neurodegenerative indications, including rare diseases.

A leader in AD disease mechanism elucidation, Siena Biotech has subsequently delivered clinical candidates for Alzheimer Disease in partnership with leading pharmaceutical companies.

Our fight to develop a disease modifying therapy against Huntington Disease, a devastating hereditary neurodegenerative disease with no cure, has lead us to clinical development of SEN196, a Sirtuin 1 inhibitor in licensed from Elixir Pharmaceuticals. The product is currently in Phase II trials in patients with HD and has achieved Orphan Drug status for HD from the FDA, the EMEA and the Department of Health and Ageing in Australia.

Siena Biotech has signed a collaboration agreement with the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), two research units under Singapore's Agency for Science, Technology and Research (A*STAR). The collaboration leverages Siena Biotech's expertise and equity of Wnt pathway modulators with ETC and SigN capacity to develop new drugs and targeted antibodies respectively, aiming to help millions of cancer and bone loss patients across the world.

Siena Biotech recently signed a strategic partnership with Aptuit taking a minority stake in Aptuit's Italian operations in Verona, Italy. Under the terms of the agreement Aptuit and Siena Biotech will work collaboratively on the development of Siena Biotech's pipeline of compounds, focused in three key therapeutic areas, including Alzheimer's disease, Huntington's disease and oncology.

Our people share the same values of diversity, integrity, knowledge, and passion which are applied both in everyday life within the community and in our commitment to improve human health according to the mission of our shareholder Monte dei Paschi di Siena Foundation.